Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This is absurd, but Yellen got exactly what
she wanted.
As i said before, i don't believe
interest rates will go up too soon or too much
although this is what the FED would like people
to think. Since Yellen knows that but she didn't like the
market's complacency, she said something about
this and the lack of volatility and now we got this.
If Tuesday's intra day low of 1925 fails to hold over the next
few days then the next support level would be at the 200 Day MA around 1900.
I am sitting on approx 50% cash in the last few weeks,
looking at some stocks and salivating but so far i am holding
myself from buying as i would rather see if the market
stabilizes or we get the 10% correction and get it over with.
CPSS - Stephens initiated coverage on Consumer Portfolio Services (NASDAQ: CPSS) with an Overweight rating and a price target of $9.00.
http://www.streetinsider.com/New+Coverage/Stephens+Starts+Consumer+Portfolio+Services+%28CPSS%29+at+Overweight/9875700.html
A number of other analysts have also recently weighed in on CPSS. Analysts at Jefferies Group initiated coverage on shares of Consumer Portfolio Services in a research note on Thursday, September 4th. They set a “buy” rating and a $9.00 price target on the stock. Analysts at Compass Point initiated coverage on shares of Consumer Portfolio Services in a research note on Tuesday, July 8th. They set a “buy” rating and a $10.00 price target on the stock.
http://www.americanbankingnews.com/2014/10/01/consumer-portfolio-services-now-covered-by-stephens-cpss/
KINS - today's volume is the largest since
Mar 30, 2012 if i am not mistaken.
Up 1.5% on 11 times average volume (145k shares).
CPSS(6.45) - bought back. Stock is oversold
here, stochastics are way down and MACD is
starting to turn up, so hopefully this is
at bottom or close to it.
Insider buys are a huge positive. I also don't think
the FED will raise rates too soon and too much so
i don't see it as an issue here.
KINS - Yes. He now owns 823k shares.
KINS - CEO bought another 1000 shares @7.97
http://ih.advfn.com/p.php?pid=nmona&article=63784823&symbol=KINS
SEV - sold most between 8.75-8.98 for
a 27% profit as it was up nicely in the last
few days and is a little overbought.
SEV - that's more like it. As opposed to
yesterday, today's volume was 5 times daily
average volume and the stock even managed
to close above the 200 day MA. up 13.7% to 9.
The stock is overbought here, but might still
have room to run in the current move. We'll see.
MBX.to/MBXBF - “So far, 2014 has been a fantastic year for Microbix,” says Kevin Koole, Microbix Director of Sales and Marketing when considering the company’s prospects for MEDICA 2014. “We have already smashed our previous annual sales record and in the process have become the world’s largest supplier of Rubella and CMV antigens. As a result, we have increased our workforce by one-third and signed several long-term contracts that will provide a significant base for our future growth”.
http://www.medica-tradefair.com/cipp/md_medica/custom/pub/content,oid,47712/lang,2/ticket,g_u_e_s_t/~/MICROBIX_RETURNS_TO_MEDICA_WITH_RECORD-BREAKING_ANTIGEN_SALES.
"I believe Microbix exemplifies Ontario's ideal of a fast growing mid-sized company," says Vaughn Embro-Pantalony, President and CEO of Microbix. "Consider that we are a high-tech life sciences company; we employ a diverse and highly skilled team of scientists and technologists; we have expanded our workforce nearly 50% in the last 12 months; we are developing innovative products including our new dengue fever antigens and molecular diagnostics products; and we have grown our export sales more than 35% in the past year."
http://www.newswire.ca/en/story/1413960/microbix-named-a-finalist-for-2014-ontario-business-achievement-award
U SNUze, you lose!
GEVO (.35) - bought it here as the
stock is oversold , stochastics are
way down, the stock hit 52wk low today @.34
and is down huge in the last 6 months. Down 15% today.
They raised $18 million @.60 only a few weeks ago.
SEV up 14% to 8.33. A move at last, but the
volume is too small. We need a lot more volume.
CAZFF (0.29) - Excellent news today:
http://finance.yahoo.com/news/caza-oil-gas-announces-results-060000685.html
The Broadcaster 29 Fed #3H horizontal 3rd Bone Spring well (the "29-3H well") reached the intended total measured depth of approximately 15,818 feet in the targeted 3rd Bone Spring Sand interval and was subsequently fracture stimulated in 40 stages beginning on September 7, 2014. Under controlled flowback the producing rates are steadily increasing, and the well produced at a 24 hour gross rate of 2,621 barrels (bbls) of oil equivalent, which is comprised of 2,062 bbls of oil and 3.36 million cubic feet of natural gas, on September 16, 2014. The well was producing on a 46/64ths adjustable choke at 1,850 pounds per square inch flowing casing pressure. This is a very strong well, and the Company anticipates a higher peak rate to be achieved in the coming days. Once a peak rate is achieved, the market will be updated accordingly. Facilities are already in place on the property, and both oil and natural gas are flowing to sales. Caza currently has a 25% working interest (approximate 17.63% net revenue interest) in the Broadcaster 29-3H well and the Broadcaster Property.
The Broadcaster Property is a 320 acre tract adjacent to the Company's West Copperline Property, which also comprises 320 acres. In addition to the producing 3rd Bone Spring pay interval, log data from the 29-3H well indicates the presence of oil and natural gas across the same potential pay intervals present at West Copperline, which include: the Brushy Canyon, Avalon Shale and 1st and 2nd Bone Spring Sand intervals. This is favorable for future development across the property. Management believes the deeper Wolfcamp formation on the property is also prospective for oil and natural gas.
http://www.malcysblog.com/ :
>>Sometimes I think I am bashing my head against a brick wall with stocks but the market, whilst always being right, can often get its timing wrong. Caza has today announced the preliminary result of the Broadcaster 29-3H well and if the share price doesn’t go through the roof it will be the opportunity of a lifetime. Still not yet at TD the well is producing 2,621 boe/d and is already going to sales. CEO Mike Ford says that this is an ‘exceptional’ result and on its own would be transformational but this is only one of a number of very good well results released by the company in recent months. Ford also states that the impressive use of new frac technologies is improving the economics considerably and so the good news goes on.
Caza tends to move in unfathomable ways, it will have a huge bounce then stay at a level for a while, at 8-9p it did then moved up to 18-23p, this must be time for another serious bounce. The value of Caza has increased substantially with recent results and the market hasn’t noticed, soon the industry will as net production screams through the magical 2/- b/d, don’t say you haven’t been warned, Caza is worth well in excess of 50p a share, more later if I get to speak to the company this afternoon.<<
KBIO - sold @1.67 for 8% profit.
MBX.to - another good day. Up 15% to .60 on
7 times average volume.
MBX.to - i took advantage of the recent
decline after the small raise and bought it
a few days ago @.44. I wanted to accumulate more
around this level, but the stock ran in the last 2 days.
Lots of potential here.
http://moatology.com/2014/04/28/microbix-biosystems-four-businesses-for-the-price-of-one/
"I’ve always been struck by how the three assets in Microbix Biosystems (TSX:MBX) could be worth at least $50-million each, while the company has a market cap of around $30-million. Nevertheless, Microbix is now cash flow positive, which may now generate market recognition."
http://biotuesdays.com/2014/04/01/in-conversation-with-tony-pullen/
PNTR - up 6% on news. Sold @7.65 for
a 20% profit.
http://finance.yahoo.com/news/pointer-telocation-expands-global-presence-125700569.html
Out @3.2. That's 45% in a little over
a week. Good enough for me.
ESCC (.34) – bought last week @.33-.35. The company
lost 13c on revenues of $12.4 for the first 6 months of 2014
vs a loss of 16c on revenues of $9.9 in the first 6 months of 2013.
Revenues for the first 6 months were up approx 25% and their Backlog is going up as well. In the end of Q2 backlog was $21.4 million, up from $19.7 on March and $17.2 million on December 2013.
In Q2 PR, the CEO said:
"With the improved backlog and strong sales prospects we still
believe that sales and overall results for 2014 will be comparable to 2013."
In 2013, their EPS was 0.11 on $29.6 in revenues. In order for the results to be comparable, they need to make approx .24c a share in Q3 & Q4 (which were the stronger Q's in 2013 as well).
"the weaker sales and resulting net loss in the first half of 2014 was primarily the result of the timing of work and deliveries on customer projects rather than a negative trend in the overall business. New bookings and the sales backlog continued to improve which creates a more encouraging outlook for the remainder of 2014."
Also, cash balances continued to improve from progress payments received on new customer orders.
Net cash provided by operating activities was $2.3 million for the first 6 months. Cash is up to $6.5 million (740k of it is restricted)
Market cap is only $3.8 million and the stock would be much higher if not for the company's pension liabilities, but they
are working on a resolution. A settlement of their pension plan
can be another catalyst:
“We have made significant progress toward the settlement of our Pension Plan liabilities through the distress termination application process. Recent correspondence with the Pension Benefit Guaranty Corporation indicates that the application process will result in a settlement of the Pension Plan liabilities on terms that will enable the Company to continue to operate as a going concern. However, the Company is uncertain of the timing or the ultimate outcome"
"The Company initiated an application process for the distress termination of the Pension Plan in accordance with provisions of the Employee Retirement Income Security Act of 1974 (“ERISA”) which it believes will result in a settlement of its Pension Plan liabilities on terms that are feasible for the Company to continue in business as a going concern through 2014 and beyond. However, as of the date of this filing, the Company is uncertain of the timing or the ultimate outcome."
KIK, great call on ELXS as usual and i hope
you make a ton on it, but after reading the
financials yesterday i couldn't bring myself to buy.
mandjb expressed my thoughts exactly.
What you saw this morning, was exactly what i wanted to see.
A few days ago there was a death cross on the chart
(50 day MA going below the 200 day MA) and the stock
was not far away from closing the November 2013 gap.
After going down so much, the stock only had another 15%
or so to close it. This morning there was a flush and the
gap is now closed. I bought today @2.2
I previously bought IPCI in May @3.67 but took
a 15% loss and waited for a reentry.
KINS - I bought more as well. Volume is
increasing the last few days and the stock
is consolidating around the $7 level.
Q3 has a tough comp (they made $.44 in 2013 including a one
time gain of .08), but it will be mainly because they
have much more shares OS this year (7.35m vs 3.9m) than last
year after their public offering.
This one is looking great IMO. I like the growth, insider
buys and dividend. I hope to see it at least @9 by
the end of the year.
OREX - sold the rest @5.72 for a 16% profit.
CRNT - up 5% to 2.25. sold for 10% profit.
PNTR - bought now @6.33. Stock is down around
15% and is way oversold here. Can't find any news
or filings so maybe just a big seller.
BSDM - Bought in the last few days around .61.
The price has been cut in half in less
than 2 months. The stock is oversold and MACD is starting
to turn up.
They raised approximately $5.2 million @.95 on July 1st.
Insider buys at much higher prices (.82-1.12) in the last few months:
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=10103827
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=9989669
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=9986479
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=9963659
Ablation Technologies Market Expected to Reach USD 10.6 Billion Globally in 2020:
http://www.transparencymarketresearch.com/pressrelease/ablation-technologies-market.htm
OREX - sold half @5.82 for 18% profit.
KBIO - bought @1.55 in the last few
days. Stock is oversold,
stochastics at bottom and MACD starting to turn up.
$59m in cash and a $51m market cap.
http://www.smarteranalyst.com/2014/07/29/william-blair-reaffirms-outperform-on-kalobios-as-sanofi-returns-global-rights-to-kb001-a/
CAZFF (0.3) - bought in the last few days.
>>Caza's revenues from oil and natural gas sales increased 489% to US$6,286,049 for the three-month period ended June 30, 2014, from US$1,067,991 for the comparative period in 2013. This also represents a quarter-on-quarter increase of 37% compared to US$4,591,507 in Q1 2014<<
>>Average net production volumes increased 320% to 937 Boe/d for the three-month period ended June 30, 2014, from 223 Boe/d for the comparative period in 2013, and have since increased to an average of 1,315 Boe/d during the month of July 2014. The Company's net aggregate production for the month of July was 40,776 Boe, which is currently ahead of the Company's forecast.<<
It seems like mgmt's goal is to eventually sell
the company:
>>Management's goal is to achieve significant growth in the Company's reserves and production, thereby raising the Company's profile in the basin and allowing shareholder value to be maximized and, if appropriate, fully matured over the short-to-medium term.<<
There is a huge summary of the results, latest wells results
and future plans in this PR:
http://finance.yahoo.com/news/caza-oil-gas-announces-second-060000035.html
Caza reveals the financial benefit of rising production as revenues jump 489%
http://www.proactiveinvestors.co.uk/companies/news/71280/update-caza-reveals-the-financial-benefit-of-rising-production-as-revenues-jump-489-71280.html
Caza - http://www.malcysblog.com/
A quick mention of 2Q results from Caza as generally these quarterlies are pretty meaningless. Not so for Caza where the recent drilling successes are streaming through to revenue and making a positive EBITDA. Revenue up 489% y/y and an EBITDA of $3.3m against a loss last time but this was up 65% on the last quarter. NGL production also up nearly 500% y/y but again up 47% q/q.
These numbers are going to transform Caza which has paid of its Yorkville commitments and will now have enough cash to go out and buy more land and participate in lease sales, a total transformation from not long ago and will have drawn the attention of many people in the US. Caza is extraordinarily cheap and like a number of E&P companies at the moment, buying the oil on the street is looking significantly cheaper than an industry purchase so watch this space.
KINS - great results and outlook:
Mr. Brodsky continued, “We feel that the second half of 2014 will continue to show direct written premium growth, and the change in our reinsurance structure will have a significant impact on net premiums written and earnings beginning in the third quarter. We were able to leverage a strengthened financial position that allowed Kingstone to retain a much larger share of the premiums we write, while not sacrificing the conservative underwriting standards that we feel provide sustainability in the long-term.”
Mr. Goldstein continued, “While we impose a maximum net written premium to capital ratio of 1.5, at June 30, 2014 this amount was .88. This leaves us considerable room to grow our premiums and still stay within our comfort zone.”
http://finance.yahoo.com/news/kingstone-companies-announces-2014-second-200500761.html
>>Realize that q2 was made up of mostly other income (Non Recurring) would of reported losses without it in my opinion.<<
This is exactly what i wrote:
"I will probably play it for a bounce but for those that
might be interested further here is what the CEO said
in Q2 results (Q2 profitability is due to a one time gain.)"
CRNT - bought today @2.03. Stock is oversold,
stochastics at bottom and MACD starting to turn up.
They did a public offering a few days ago @2 with
no warrants.
http://finance.yahoo.com/news/ceragon-networks-ltd-prices-underwritten-004100077.html
I will probably play it for a bounce but for those that
might be interested further here is what the CEO said
in Q2 results (Q2 profitability is due to a one time gain.):
"We are pleased to report a continuation of the improved booking pattern that began in the first quarter, when bookings were 19% above the average quarterly bookings in 2013," said Ira Palti, President and CEO of Ceragon. "Bookings in the second quarter were 30% higher than the 2013 quarterly average. This provides tangible evidence of a further improvement in revenues in the second half, compared with the first half of 2014. We are especially encouraged by the penetration of the new IP-20 platform, which accounted for 39% of total bookings during the first six months of 2014. We believe the second half of 2014 will mark the beginning of a sustainable uptrend in revenues, followed by a return to profitability with substantial operating leverage, based on a lower expense profile from the recent restructuring.
"In addition to the orders in hand from two quarters of very strong bookings, we expect significant additional orders during the second half of 2014 related to customers' modernization and expansion programs for which we have already been chosen as a vendor. Therefore, with demand picking up faster with larger orders than we anticipated, we are moving immediately to raise additional equity capital in order to ensure that we have the necessary working capital and financial flexibility to fund our growth and avoid any potential liquidity issues."
http://finance.yahoo.com/news/ceragon-networks-reports-second-quarter-120000340.html
Re: SEV, PQ, PCMI and quarterly reports.
hweb, yes, i saw your post about Gabelli and read
about him a few weeks ago.
IMO, the vast majority of stocks are not worth holding
into reports. Most of those who do have a good report,
tend to go up modestly while a miss can cost much more,
especially with the market weakness in the last few weeks.
Your excellent calls on EVOL & CTP are another
good example. One could have made 20-30% on both before
the reports and sell them without taking the risk
of holding through a report.
They both posted good results and one could have bought them at the same price or lower after the report without taking a risk.
I am much more comfortable buying SEV after the report
and see if they will post some good news in the next 3
months without being exposed to a quarterly report.
PQ - decided to hold it through the report because
i thought it will be good. Well, i sold for a 10% loss
and it is down another 8% since then.
PCMI - i almost bought it before the report, but finally
decided that it was not worth it. We'll see what the stock
does today after the disappointment. It is worth
putting on watch for a supposedly better second half
and that big one time gain on a sale of a property.
SEV - bought @6.91. The stock closed the
gap i was talking about in previous post,
the price is below the price paid in the rights
offering and the stock is also oversold now.
Out MTEX around 12 and surprised that i got out
without a loss after that crappy report.
Bought OREX @4.91. PDUFA on September 11.
The stock is close to being oversold, stochastics
are also way down and previous bottom in April was
around 4.75.
Orexigen Receives Three Month Extension of FDA NB32 Review
SAN DIEGO, June 11, 2014 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (OREX) today announced that the United States Food and Drug Administration (FDA) has extended its review of the resubmitted New Drug Application (NDA) for NB32, the Company's investigational medication being evaluated for weight loss. The new Prescription Drug User Fee Act (PDUFA) action date has been set for September 11, 2014.
The FDA has indicated that the review extension is needed to reach agreement on the post-marketing obligation related to the previously agreed upon evaluation of cardiovascular (CV) outcomes for NB32. The NDA resubmission package includes interim safety and CV outcomes data from the ongoing 8,900 patient Light Study. Discussions around the package insert and other post-marketing obligations are ongoing.
"We are working expeditiously with the FDA to finalize the review," said Michael Narachi, CEO of Orexigen. "We are encouraged by the high level of engagement with the FDA, and are confident that we can reach agreement on the remaining post-marketing obligation."
Orexigen management will host a conference call and webcast to discuss this update today at 8:00 a.m. Eastern time. The live call may be accessed by phone by calling 1 (800) 708-4540 (domestic) or 1 (847) 619-6397 (international), participant code 37498115. The webcast can be accessed live on the investor relations section of the Orexigen web site at http://www.orexigen.com/ and will be archived for 14 days following the call.
yhoo.it/1inpkqM
Sold CPSS. I bought it for a bounce and
11% in 3 days is good enough for me.
CPSS - up 10% now. Maybe They were liquidating
their last shares and this is why we got cheap
shares in the last few days. Now that they are
gone, the stock is bouncing.
CPSS - nice! Here is a presentation from today's 8K:
http://app.quotemedia.com/quotetools/showFiling.go?webmasterId=500&name=CONSUMER%20PORTFOLIO%20SERVICES%20INC:%208-K,%20Sub-Doc%202&link=http%3A//quotemedia.10kwizard.com/filing.xml%3Frid%3D23%26ipage%3D9718355%26DSEQ%3D2%26SQDESC%3DSECTION_EXHIBIT%26doc%3D2&cp=on&type=HTML
Sold a lot today between .08 -.11. for a 4-10 bagger
(bought @.01-.02).
Can't find any filing or news and the huge volume
is an opportunity for me to sell since i owned 4.8%
of the shell.